Peter Sciberras

Mr. Peter Sciberras

University of Malta
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PSPeter Sciberras
Peter Sciberras
LGLaura Grech
Laura Grech
GGGodfrey Grech
Godfrey Grech
Protein phosphatase 2A (PP2A) is a ubiquitously expressed intracellular serine/threonine phosphatase. Deregulation of PP2A is a common event associated with adenocarcinomas of the colon and rectum. We have previously shown that breast cancer cell lines are sensitive to the PP2A activator FTY720, and that sensitivity is predicted by high Aurora kinase A (AURKA) mRNA expression. In this study, we hypothesized that high relative AURKA expression could predict sensitivity to FTY720-induced apoptosis in colorectal cancer (CRC). The CRC cell lines NCI H716, COLO320DM, DLD-1, SW480, and HT-29 show a high relative AURKA expression as compared to LS411N, T84, HCT116, SW48, and LOVO. Following viability assays, LS411N, T84, HCT116, and SW480 were shown to be sensitive to FTY720, whereas DLD-1 and HT-29 were non-sensitive. Hence, AURKA mRNA expression does not predict sensitivity to FTY720 in CRC cell lines. Differentially expressed genes (DEGs) were obtained by comparing the sensitive CRC cell lines (LS411N and HCT116) against the non-sensitive (HT-29 and DLD-1). We found that 253 genes were significantly altered in expression, and upregulation of CERS4, PPP2R2C, GNAZ, PRKCG, BCL2, MAPK12, and MAPK11 suggests the involvement of the sphingolipid signaling pathway, known to be activated by phosphorylated-FTY720. In conclusion, although AURKA expression did not predict sensitivity to FTY720, it is evident that specific CRC cell lines are sensitive to 5 µM FTY720, potentially because of the differential expression of genes involved in the sphingolipid pathway.

5 December 2024 in Journal of Adolescent and Young Adult Oncology
Verified
Journal Article
Closed access
PSPeter Sciberras
Peter Sciberras
KCKirsten Cromie
Kirsten Cromie
ARAnna Radford
Anna Radford
AGAdam Glaser
Adam Glaser
RFRichard G. Feltbower
Richard G. Feltbower
NHNicola F Hughes
Nicola F Hughes
Introduction: Adolescents and young adults (AYA) are a unique subgroup of patients who experience cancer at the interface between pediatric and adult oncology services. Central nervous system (CNS) tumors are the leading cause of cancer-related morbidity and mortality in this group. Socioeconomic status and ethnicity are known to impact CNS tumor survival in patients of all ages. Studies reporting AYA CNS survival outcomes by ethnicity and area-based deprivation, however, are lacking in the United Kingdom (UK). Methods: Using cancer registration data for 351 patients (12–29 years) who received systemic chemotherapy for a high-grade malignant CNS tumor in England between April 2014 and December 2018, we quantified differences in survival at 1, 2, and 3 years post-diagnosis by ethnicity and area-based socioeconomic status. Results: Lower survival estimates were seen for non-White ethnicity and lower socioeconomic groups. Three-year survival was 64.4% (95% CI 58.3–69.9) for White patients but 46.6% (95% CI 29.9–61.7) for non-Whites and 64.0% (95% confidence interval [CI] 49.0–75.7) and 62.9% (95% CI 50.7–72.8) in those from the two least deprived fifths compared to 50.2% (95% CI 36.1–62.7) and 56.1% (95% CI 42.4–67.7) in the two most deprived groups. Conclusion: Our study is the first to show the existence of health disparities in AYA treated with chemotherapy for a primary CNS tumor in England, where patients from ethnic minorities and deprived areas had worse survival rates than their White and socioeconomically advantaged counterparts. These findings call for further research into the underlying reasons behind survival differences between sociodemographic groups to improve survivorship outcomes.

19 August 2025 in Scottish Medical Journal
Verified
Journal Article
Closed access
PSPeter Sciberras
Peter Sciberras
PPPhilip Paris
Philip Paris
GMGloria Montebello
Gloria Montebello
RCRebecca Calleja
Rebecca Calleja
RBRebecca Bugeja
Rebecca Bugeja
JCJohn Camilleri-Brennan
John Camilleri-Brennan
Background and Aims: To determine which factors were associated with and predictive of an advanced stage at diagnosis and emergency mode of presentation in colorectal cancer patients. Methods and Results: A total of 587 consecutive patients discussed at multidisciplinary team meetings between January 2017 and December 2019 at an acute hospital in Scotland were included. The effect of predefined variables on stage and mode of presentation was analysed using logistic regression. 55.4% of patients had advanced disease and 19.7% of patients presented as an emergency: these were more likely to have advanced disease (odds ratio (OR) 1.64, 95% confidence interval (95%CI) 1.02–2.62, p = 0.04) compared to the 22.3% diagnosed at screening (OR 0.33, 95%CI 0.21–0.52, p < 0.001). Individuals with affected first-degree relatives were more likely to present with advanced disease (OR 2.39, 95%CI 1.06–5.40, p = 0.04). The association of deprivation and tumour site with advanced disease at presentation was significant ( p = 0.04 and p = 0.013, respectively). The likelihood of presenting as an emergency increased with age (OR 1.03, 95%CI 1.01–1.05, p = 0.003) and with advanced disease (OR 2.15, 95%CI 1.37–3.38, p < 0.001). Again, the relationship between tumour site and emergency presentation was significant ( p = 0.002). Conclusion: Further efforts are required to increase screening uptake, particularly amongst higher risk groups, to detect disease at an early stage and reduce the number of patients presenting as emergencies.